Kornimate/medical-research-clean huggingface dataset:
early risk of asthma in children exposed to in-utero maternal obesity

Conditions: Asthma; Children; Obesity; Maternal

Summary: this study seeks a better understanding of the pathogenesis of asthma in early life. the aim of this project is to determine whether the offspring of obese mothers at 3 years of life have increased the risk of asthma compared to children whose mothers were not obese and whether this increased risk is associated with a programming altered immune reactivity at birth.

the general objectives of this study are: 1. to determine whether the increased risk of asthma in children born from a pre-pregnant obese mother can be observed at 3 years of life and whether this increased risk associated with altered plasma levels of immune mediators at birth. 2. to explore in children born from pre-pregnant obese mother whether monocyte physiology and m1-m2 polarization present an altered response and expression of asthma-related immune-modulations at birth. 3. to study in neonates born from pre-pregnant obese mother whether the in vitro expression of tnfα, il12, il-10 and il-4rα in monocytes associates with changes in the dna methylation status in the promoter regions of those genes. the study is performed in accordance with the helsinki declaration, and the study protocol was accepted by institutional review boards at school of medicine of the pontificia universidad católica de chile.

Eligibility criteria:
inclusion criteria: * women who receive care in any of the 12 public health care centers in la florida and puente alto and give birth in the sotero del río hospital. * singleton pregnancy of fewer than 14 weeks of gestation at the first antenatal visit. * 18 years or older exclusion criteria: * pregnant women with overweight (bmi 25-30) before 14 weeks. * women that have a premature birth, cardio-respiratory disorder or neurological defects of the neonate. * women that develop gestational diabetes and hypertension during pregnancy
intra-arterial prostaglandin therapy in non-occlusive mesenteric ischemia

Conditions: Non-Occlusive Mesenteric Ischaemia (NOMI)

Summary: minimal invasive intra-arterial prostaglandin therapy is currently being offered as an established and safe treatment approach for non-occlusive mesenteric ischemia (nomi). so far, there are no data that prospective evaluate clinical response parameters of this method and corresponding criteria for response. the investigators are therefore planning a prospective observational study on nomi patients with the aim to collect 1. routine clinical data, 2. data from advanced angigraphic imaging and 3. data from blood biomarkers of intestinal ischemia before/at implementation of intra-arterial vasodilatory therapy. from these three data packages, the investigators hope to subsequentially derive criteria to better predict response to therapy.


Eligibility criteria:
inclusion criteria: - persistent shock: norepinephrine dose \> 0.2ug/kg/min over \> 48hrs and * intestinal failure: paralytic ileus \> 24hrs despite neostigmine therapy or * new onset progressive organ failure (2 out of six criteria): norepinephrine dose increase, rise in serum lactate, decrease in horowitz index, new renal replacement therapy, rise in bilirubin, rise in inr, or all of the following: rise in alt, ast, ck and ldh exclusion criteria: * patients \< 18 years old * pregnancy

Keywords: non-occlusive mesenteric ischemia shock intra-arterial prostglandin therapy
enhancing community participation through peer-delivered decision support

Conditions: Severe Mental Disorder

Summary: the purpose of this study is to pilot test a peer-delivered decision support intervention ("peer decision coaching") designed to enhance decision-making about community participation among young adults with serious mental illness (smi).

the overarching goal of this study is to pilot test a peer-delivered decision support intervention ("peer decision coaching") designed to enhance decision-making about community participation among young adults with serious mental illnesses (smi). we will use a single-group, pre-post, convergent mixed methods design to explore implementation and whether and how the intervention impacts decision-making and community participation outcomes. we will aim to recruit 40 participants in this intervention study. this design will enable us to link themes regarding participants' experience of the intervention with quantitative measures of decision-making and community participation.

Eligibility criteria:
inclusion criteria: * 18-30 years of age; * experiencing a smi, as determined by: (a) self-reported psychiatric diagnosis of schizophrenia-spectrum or major affective disorder, and (b) self-reported current or past functional impairment due to experiencing mental health challenges in one or more major life areas (i.e., work school, social activities) * able to identify at least 2 areas of community participation that individuals want to be doing more in in the next 6 months * current sufficiency of community participation (i.e., number of important participation areas done enough / number of important participation areas) of 50% or less. exclusion criteria: * unable to provide informed consent, as assessed by research staff using an active recall method * limited ability to act on decisions due to self-reported legal, residential, or guardianship restrictions.

Keywords: peer specialists, decision support techniques, young adult
arthroscopic synovectomy combined with dmards in the treatment of refractory elbow rheumatoid arthritis

Conditions: Rheumatoid Arthritis of Ankle

Summary: rheumatoid arthritis (ra) is an autoimmune disease characterized by chronic and aggressive polyarthritis. the prevalence of ra in china is about 0.42%. arthroscopic synovectomy (as) is an important method to save the function of joint in the treatment of refractory ra. the clinical trial is to study the value of as combine with dmards in the early stage of refractory ra.


Eligibility criteria:
inclusion criteria: * the patients who fulfilled the 1987 acr（american college of rheumatology) or 2010 acr/eular（european league against rheumatism） ra classification criteria. * the age is more than 18 years old and less than 60 years old. * they received stable traditional dmards (including chrysopidae, leflunomide, sulfasalazine, hydroxychloroquine, eilamod) or biological dmrads (including tumor necrosis factor antagonists, il(interleukin)-6 receptor antagonists, cd20 monoclonal antibodies) for at least 6 months. * the disease is still in the active stage, which means the disease activity score (das28) is more than 3.2, and the elbow joint function is obviously limited. * the patient agreed to undergo arthroscopic synovectomy. * no contraindications were found. exclusion criteria: * the disease is in remission. * the patient has contraindications. * arthroscopic synovectomy was performed in different patients.

Keywords: rheumatoid arthritis arthroscopic synovectomy
patient satisfaction after patient-specific jawline augmentation

Conditions: Congenital Deformity of Face; Post-traumatic Deformity

Summary: the survey studies patient satisfaction after titanium patient specific jawline augmentation in congenital, post-trauma, deformity and transgender/cosmetic jaw angle/border deficiencies.

additively manufactured titanium implants have been pre-designed in the hospital department, further designed and manufactured by 2 belgian companies. the issue is if all patients have satisfactory perception of the improvement of their morphology and the actual outcome of the procedure, and how theur social ineractions are perceived today.

Eligibility criteria:
inclusion criteria: - all lower jaw augmentation implants exclusion criteria: - n/a

Keywords: satisfaction jawline augmentation transgender cosmetic jaw angle
oxaliplatin and cetuximab in first-line treatment of metastatic colorectal cancer (mcrc)

Conditions: Neoplasm Metastasis; Colorectal Cancer

Summary: this is an open label, randomized, controlled, multicenter phase ii study comparing 5-fu/fa + oxaliplatin (folfox-4) + cetuximab versus 5-fu/fa + oxaliplatin as first-line treatment for epidermal growth factor receptor (egfr)-expressing mcrc.


Eligibility criteria:
inclusion criteria: * first-line mcrc * egfr positive * bi-dimensional measurable index lesion exclusion criteria: * previous exposure to egfr-targeting therapy * previous oxaliplatin-based therapy * previous chemotherapy for colorectal cancer except adjuvant treatment with progression of disease documented \> 6 months after end of adjuvant treatment * radiotherapy * surgery * any other investigational drug in the 30 days before randomization * brain metastasis and/or leptomeningeal disease * acute or sub-acute intestinal occlusion or history of inflammatory bowel disease

Keywords: folfox-4 cetuximab first-line mcrc egfr positive metastatic crc
left ventricular aneurysms in children

Conditions: Congenital Disorders

Summary: collect data to support "standard of care possibility" of extracardiac repair with closure of intracavitary communication and plication of the aneurysm as probably safest surgical repair for left ventricular aneurysms.

ventricular aneurysms in the pediatric population are rare and no standardized method of treatment exists. we plan on reviewing five patient charts between the dates of 6.30.02 and 6.30.04 as to causes of aneurysms. the patient charts selected will be in the following "aneurysm categories": mostly occur after: ross/ross-konno procedures modified rastelli-type interventricular tunnels repeated resections of subaortic stenosis and possibly after: myocardial ischemia trauma drainage of abscess in infective endocarditis progressive herniation of endocardium mostly located: in lv outflow tract we plan on collecting echocardiograms and / or cardiac catheterizations data in order to confirm the diagnosis of an aneurysm. we will also collect the following information: * procedures including the dates performed * medications * physical exam findings * weight * gestational age * outcome

Eligibility criteria:
inclusion criteria: * aneurysms between 6.30.2002 and 6.30.2004 exclusion criteria: * those children who do no meet inclusion criteria

Keywords: pediatric cardiac aneurysms left ventricular aneurysms surgical repair for lv aneurysms
stereotactic ablative radiation for oligo-progression of urothelial cancer

Conditions: Urothelial Cancer

Summary: to evaluate the benefit of sabr for oligo-progressive metastatic urothelial cancer.

oligo-progressive urothelial cancer with limited disease burden and progression on an anti-pd-1/l1 immune checkpoint inhibitor.

Eligibility criteria:
inclusion criteria: * patients must be at least 18-years-old * ecog performance status 0-2 * patients must have pathology-proven metastatic urothelial carcinoma, with tissue sampling of at least the primary tumor. tissue sampling of each presumed metastatic site is not necessary, provided that the patient already has a confirmed diagnosis of urothelial cancer. * patients must be on immune checkpoint inhibitor therapy with radiographic scans to verify oligo-progression of at least one and ≤ 6 sites of disease per recist 1.1. * any of the currently fda-approved pd-1/pd-l1 inhibitors are allowed. these include pembrolizumab, nivolumab, atezolizumab, avelumab, and durvalumab. * at least 1 metastatic lesion must show stable disease, partial response or complete response per recist 1.1. * patients must be able to understand and willing to sign written informed consent. * patients must have acceptable tolerability of ongoing therapy as decided by the treating medical oncologist. * patients must have a desire to continue ongoing therapy. * women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. * a female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: * has not undergone a hysterectomy or bilateral oophorectomy, or has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months). * should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. exclusion criteria: * inability to receive further immune checkpoint inhibitor therapy * anticipated survival of fewer than 12 weeks * daily steroid requirement of \> 10 mg prednisone or prednisone-equivalent. steroid replacement therapy for adrenal insufficiency is permitted. * uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirements. * subjects must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.
genetic predictors of variability in the drug-drug interaction between darunavir/ritonavir and pravastatin

Conditions: HIV Infections; Hyperlipidemia

Summary: pravastatin (pravachol) is approved by the food and drug administration (fda) and is used to treat high cholesterol. darunavir (prezista) and ritonavir (norvir) are approved by the food and drug administration (fda) to treat hiv infection. when darunavir and ritonavir are given with pravastatin, they can increase the blood levels of pravastatin. the degree of this interaction varies from person to person. the way that darunavir and ritonavir interact with pravastatin may be affected by a person's genetic make-up. genetic factors (or dna) are those that people are born with and that make each person unique. genetic differences are the reason why one person's body traits such as height and hair color are different from another person's body traits. genetic differences can also affect the way a medication works in the body or the way two medications interact in the body. the purpose of this clinical study is to determine if a person's genetic make-up affects the way darunavir and ritonavir interact with pravastatin in the body.


Eligibility criteria:
inclusion criteria: * healthy, hiv-negative volunteers exclusion criteria: * currently active or chronic cardiovascular, hepatic, renal, pancreatic, gastrointestinal, neurologic, hematologic, psychiatric, metabolic, respiratory, inflammatory, or infectious disease * chronic pancreatitis * history of rhabdomyolysis * history of statin-associated myopathy * active malignancy * history of significant skin disease, food allergy, drug allergy, dermatitis, eczema, psoriasis * pregnancy/breastfeeding * hiv positive and/or aids * serum creatinine grade 1 or greater (≥ 1.1 x upper limit of laboratory normal range \[uln\]); * hemoglobin grade 1 or greater (≤ 10.9 g/dl); * platelet count grade 1 or greater (≤ 124.999 x 109/l); * absolute neutrophil count grade 1 or greater (≤ 1.3 x 109/l); * aspartate aminotransferase (ast) or alanine aminotransferase (alt) grade 1 or greater (≥ 1.25 x uln); * total bilirubin grade 1 or greater (≥ 1.1 x uln) * serum lipase grade 1 or greater (≥ 1.1 x uln) * serum amylase grade 1 or greater (≥ 1.1 x uln) * any other laboratory abnormality of grade 2 or above

Keywords: hiv pravastatin darunavir ritonavir genetic
evaluation the effectiveness of ru-yi-jin-huang powder for the radiation-induced dermatitis.

Conditions: Radiation Dermatitis

Summary: radiation-induced dermatitis is the most common complication of radiotherapy for cancer treatment. however, there is no satisfactory management to deal with the problem. ru-yi-jin-huang powder is one of most common topical tcm drug to treat skin diseases but lack of evidence to support efficacy. the aim of this trial is to evaluate the effectiveness of ru-yi-jin-huang powder for radiation-induced dermatitis.

the common management of head and neck cancer are concurrent chemoradiotherapy (ccrt) after surgical section. radiation-induced dermatitis is the most common complication of radiotherapy for cancer, affecting approximately 95 percent of patients receiving radiotherapy. the skin changes include erythema, edema, pigment changes, hair loss, and dry or moist desquamation. it may cause xerostomia, hard food taking, severe infection to delay the completion of course of treatment. although, there are lots of topical drug to deal with radiation dermatitis, there is no best way to manage the skin problems. ru-yi-jin-huang powder is one of most common topical tcm drug to treat skin ulcer, joint swelling or other infective or inflammatory diseases. some study showed that ru-yi-jin-huang powder can be used to decrease edema or swelling, pain relief, decrease phlebitis or mumps. however, there is no related evidence to support ru-yi-jin-huang powder for radiation dermatitis. thus, the aim of the study is to evaluate the effectiveness of ru-yi-jin-huang powder for radiation-induced dermatitis.

Eligibility criteria:
inclusion criteria: * stage 3 or 4 of head and neck cancer or nasopharyngeal cancer with pathological confirmed malignancy undergoing concurrent chemoradiotherapy more than 20 times or radiation dermatitis \> ctcae grade 2. * more than 18 years old. * vas score \> 6 with poor response to narcotics. * estimated survival time of \> 6 months. * be suitable for tcm topical treatment after evaluation by tcm physicians. * willingness to joint this trial and sign consent form of study. exclusion criteria: * non-head and neck cancer or have not receive ccrt. * not be suitable for ru-yi-jin-huang topical treatment after tcm physicians evaluation. * history of allergy to tcm topical use. * poor conscious to answer questionnaires. * pregnancy. * kps \< 30.

Keywords: radiation dermatitis
symptom monitoring and menopausal symptoms

Conditions: Menopause

Summary: a recent systematic review suggested that symptom monitoring can result in reductions in menopausal symptoms and improvements in health-related behaviours. to date, no studies have experimentally investigated whether symptom monitoring could be beneficial as an intervention for menopausal women. one hundred menopausal women were randomised into either a monitoring-intervention or control group. a mixed between/ within design was employed, with group membership (i.e., monitoring-intervention or control) as the between-subjects component, and time (i.e., baseline and 2-weeks follow-up) as the within-subjects component. dependent variables included symptom reductions and emotional reactions. secondary outcomes included help-seeking, communication, medical decision-making, health awareness, self-efficacy, and health anxiety.


Eligibility criteria:
inclusion criteria: * women * aged 18+ * reporting at least 2 menopausal hot flushes per day * self-reported peri- or post-menopausal status. exclusion criteria: * male * under age 18 * reported fewer than 2 hot flushes per day * does not self-report peri- or post-menopausal status.

Keywords: menopause hot flushes women's health symptom monitoring
validation of transvaginal tactile imaging

Conditions: Pelvic Organ Prolapse

Summary: the purpose of this study is to validate safety and effectiveness in assessment of the female pelvic floor tissue, and, assess the ability of vaginal tactile imager (vti) to detect early prolapse conditions and characterize the outcome of reconstructive surgery.

1. the device will detect significant differences in tissue elasticity and anatomy for women with normal pelvic floor versus women with prolapse stage 1. 2. the device will detect significant differences in tissue elasticity and anatomy for patients before and after reconstructive surgery. 3. the device will detect significant differences in tissue elasticity and anatomy among 3 groups of patients with prolapse stages 1, 2 and 3. 4. the device will detect significant differences in tissue elasticity among 3 control groups with normal pelvic floor conditions (nulliparous women at age 21-30, parous women at age 31-40, and postmenopausal women).

Eligibility criteria:
inclusion criteria: * subject is female of 21 years or older and has at least one of the following * no evidence of pelvic organ prolapse and no prior pelvic surgery * stage 1 or greater pelvic organ prolapse affecting one or more vaginal compartments and no prior pelvic surgery * stage 2 or greater pelvic organ prolapse affecting one or more vaginal compartments and reconstructive surgery is scheduled exclusion criteria: * active skin infection or ulceration within the vagina * presence of a vaginal septum; * active cancer of the colon, rectum wall, cervix, vaginal, uterus or bladder; * ongoing radiation therapy for pelvic cancer; * impacted stool * recent (less than three months) pelvic surgery; * significant pre-existing pelvic pain including levator ani syndrome, severe vaginismus or vulvodynia; * severe hemorrhoids * surgically absent rectum or bladder * significant circulatory or cardiac conditions that could cause excessive risk from the examination as determined by attending physician

Keywords: pop pelvic floor pelvic organ prolapse
tear osmolarity clinical utility in dry eye disease

Conditions: Dry Eye

Summary: millions of people suffer from dry eye disease, causing symptoms such as redness, burning, feeling of sand or grit in the eye and light sensitivity. dry eye disease occurs when your eyes do not produce enough tears or produce poor quality tears. this can happen for a number of reasons, including aging, hormonal changes in women and side effects of diseases or medications. it is now possible to objectively measure the degree of dry eye disease by collecting a tiny sample of tears from the corner of the eye and then measuring the amount of salt in the tears (termed osmolarity). we aim to establish the overall levels of raised and normal tear osmolarity in people presenting to the eye clinic with complaints of dry eye, and relate this to other factors such as symptoms, topical and nutritional medication and dry eye treatment.

this study will investigate the efficacy of two treatment non-pharmaceutical therapies (tear drop alone, tear drop combined with omega 3 nutritional supplement and warm compresses) for dry eye reporting patients against a control (saline) over a 3 month period. a relatively new clinical measure (osmolarity) will be performed alongside traditional tear film volume, tear film stability, gland integrity and ocular surface damage measures to determine how this influences symptomatic complaints.

Eligibility criteria:
inclusion criteria: * dry eye symptoms speed \>8 exclusion criteria: * unable to participate in 90 days therapy * allergic to therapy * on medication known to affect ocular surface / tear film * had ocular trauma, infection or surgery * diagnosed with a medical condition known to affect ocular surface / tear film